Zobrazeno 1 - 10
of 4 882
pro vyhledávání: ''
Autor:
Sarah J. Alger, Ana Armenta Vega, Charity Juang, Cynthia A. Kelm-Nelson, Sharon A. Stevenson, Lauren V. Riters
Publikováno v:
Behav Neurosci
Long-term social bonds are critical for survival and reproductive success in many species. Although courtship and pair-bond formation are relatively well studied, much less is known about the neural regulation of behaviors that occur after pair bondi
Autor:
Julien Mazieres, Patrik Vitazka, Lyudmila Bazhenova, Pasi A. Jänne, Misako Nagasaka, DESTINY-Lung Trial Investigators, Enriqueta Felip, Luis Paz-Ares, Ryota Shiga, Yingkai Cheng, Yasushi Goto, Kapil Saxena, Kazuhiko Nakagawa, Maurice Pérol, Javad Shahidi, Jose M. Pacheco, Bob T. Li, David Planchard, Hibiki Udagawa, Egbert F. Smit, Suddhasatta Acharyya, Andreas Saltos
Publikováno v:
DESTINY-Lung01 Trial Investigators 2022, ' Trastuzumab deruxtecan in HER2-mutant non–small-cell lung cancer ', New England Journal of Medicine, vol. 386, no. 3, pp. 241-251 . https://doi.org/10.1056/NEJMoa2112431
N Engl J Med
New England Journal of Medicine. MASSACHUSETTS MEDICAL SOC
New England Journal of Medicine
The New England journal of medicine, vol 386, iss 3
New England Journal of Medicine, 386(3), 241-251. Massachussetts Medical Society
N Engl J Med
New England Journal of Medicine. MASSACHUSETTS MEDICAL SOC
New England Journal of Medicine
The New England journal of medicine, vol 386, iss 3
New England Journal of Medicine, 386(3), 241-251. Massachussetts Medical Society
Background Human epidermal growth factor receptor 2 (HER2)-targeted therapies have not been approved for patients with non-small-cell lung cancer (NSCLC). The efficacy and safety of trastuzumab deruxtecan (formerly DS-8201), a HER2 antibody-drug conj
Autor:
Sunil J. Advani, Hyunho Yoon, Rowan Ustoy, Mayra Yebra, Vipul R. Sheth, Sudeep Banerjee, Michael Heinrich, Christian M. Metallo, Joseph A. Aguilera, Sangkyu Noh, Scott M. Lippman, Razelle Kurzrock, Chih-Min Tang, Olivier Harismendy, Paul T. Fanta, Adam M. Burgoyne, Avi Kumar, Thekla Cordes, Shruti Bhargava, Sam Li, Jason K. Sicklick, Christopher L. Corless
Publikováno v:
Clin Cancer Res
Clinical cancer research : an official journal of the American Association for Cancer Research, vol 28, iss 1
Clinical cancer research : an official journal of the American Association for Cancer Research, vol 28, iss 1
Purpose: Gastrointestinal stromal tumor (GIST) is the most common sarcoma of the gastrointestinal tract, with mutant succinate dehydrogenase (SDH) subunits (A–D) comprising less than 7.5% (i.e., 150–200/year) of new cases annually in the United S
Publikováno v:
Neuropsychopharmacology
Synthetic cannabinoid receptor agonists (SCRAs) are an evolving class of new psychoactive substances found on recreational drug markets worldwide. The indole-containing compound, 5F-MDMB-PICA, is a popular SCRA associated with serious medical consequ
Publikováno v:
Reprod Sci
As a key mechanism in fibrinolysis and tissue remodeling, the plasminogen activator system has been suggested in the process of endometrial shedding and tissue remodeling. Previous studies have explored the role of estrogen, progesterone, and androge
Publikováno v:
CNS Drugs
Trace amines, including β-phenylethylamine (β-PEA), p-tyramine (TYR), tryptamine (TRP) and p-octopamine (OCT), represent a group of amines expressed at low levels in the mammalian brain. Given the close structural similarities to traditional monoam
Autor:
Natalia Jura, Devan Diwanji, Tarjani M. Thaker, Raphael Trenker, David A. Agard, Kliment A. Verba, Feng Wang
Publikováno v:
Nature, vol 600, iss 7888
Nature
Nature
Human epidermal growth factor receptor 2 (HER2) and HER3 form a potent pro-oncogenic heterocomplex1–3 upon binding of growth factor neuregulin-1β (NRG1β). The mechanism by which HER2 and HER3 interact remains unknown in the absence of any structu
Autor:
Lyndsey S. Crump, Traci R. Lyons, Elena Shagisultanova, Peter Kabos, Virginia F. Borges, Aryana R Rasti, Michelle Borakove, Benjamin A Harrison, Jessica K. Hall
Publikováno v:
Mol Cancer Ther
Breast cancers that express hormonal receptors (HR) and HER2 display resistance to targeted therapy. Tumor-promotional signaling from the HER2 and estrogen receptor (ER) pathways converges at the cyclin D1 and cyclin-dependent kinases (CDK) 4 and 6 c
Autor:
Denise M. Wolf, Jane Perlmutter, Judy C. Boughey, A. Jo Chien, Meredith Buxton, Gillian L. Hirst, Douglas Yee, Angela DeMichele, Andres Forero-Torres, Scott M. Berry, Erin D. Ellis, Anthony D. Elias, Julia Wulfkuhle, Michael Alvarado, Christina Yau, Stacy L. Moulder, Nola M. Hylton, Rita Nanda, Amy Wilson, Adam Asare, Debu Tripathy, Claudine Isaacs, Melissa Paoloni, Rosa I. Gallagher, Laura J. Esserman, Richard Schwab, W. Fraser Symmans, Cheryl Ewing, Laura J. van't Veer, Jeffrey B. Matthews, Teresa Helsten, Julia L. Clennell, Barbara Haley, Emanuel F. Petricoin, Katherine Steeg, Smita Asare, Ashish Sanil, Rachel L. Yung, Erin P. Crane, Erin Roesch, Hyo S. Han, Ruby Singhrao, Michelle E. Melisko, Hope S. Rugo, Kathy S. Albain, Donald A. Berry, Anne M. Wallace, Julie E. Lang, Amy S. Clark, Kathleen Kemmer, Lamorna Brown-Swigart
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-11 (2021)
Nature communications, vol 12, iss 1
Nature Communications
Nature communications, vol 12, iss 1
Nature Communications
HER2-targeted therapy dramatically improves outcomes in early breast cancer. Here we report the results of two HER2-targeted combinations in the neoadjuvant I-SPY2 phase 2 adaptive platform trial for early breast cancer at high risk of recurrence: ad
Autor:
Nikita Francis, Jeremy C. Borniger
Publikováno v:
Trends Neurosci
The initiation, progression, and metastatic spread of cancer elicits diverse changes in systemic physiology. In this way, cancer represents a novel homeostatic challenge to the host system. Here, we discuss how the hypothalamus, a critical brain regi